No Data
No Data
ZAI LAB: NOTICE OF AUDIT COMMITTEE ACTION AND DATE OF PUBLICATION OF THIRD QUARTER 2024 RESULTS ANNOUNCEMENT
Is Zai Lab (NASDAQ:ZLAB) Using Too Much Debt?
Zai Lab's Schizophrenia Treatment KarXT Meets Primary Endpoint in Phase 3 Trial
Express News | Zai Lab Reports Topline Data From Phase 3 Bridging Trial Evaluating KarXT For Schizophrenia In China; KarXT Demonstrated A Statistically Significant 9.2-Point Reduction In PANSS Total Score From Baseline At Week 5 Compared To Placebo, Trial Met All...
Express News | Zai Lab Ltd - to Submit Nda for Karxt to Nmpa in Early 2025
Express News | Zai Lab Ltd - Karxt Shows 9.2-Point Reduction in Panss Total Score at Week 5 Vs Placebo
No Data
No Data